Xintaropoulou C, et al. - Researchers assessed if the expression of molecular components (GLUT1, HKII, PKM2, LDHA) of the glycolytic pathway vary in the ovarian cancers. They also assessed the efficacy of targeting this pathway in ovarian cancer cell lines with inhibitors. Compared with non-high grade serous ovarian cancer (HGSOC), HGSOC showed higher mean expression levels of GLUT1 and HKII. In a concentration-dependent manner, reduced cell proliferation induced by inhibitors of the glycolytic pathway (STF31, IOM-1190, 3PO, and oxamic acid) was seen in platinum-sensitive and platinum-resistant HGSOC cell line models. Overall, targeting the glycolytic pathway in ovarian cancer was further supported in this study, and several useful combinations were identified.